This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Social Anxiety Stack
Anxiolytic / Social Loosener / Performance Anxiety / Inhibition Reduction
Overview
What is Social Anxiety Stack?
A curated set of anxiolytic and adrenergic-dampening compounds Scientific Sean recommends for situational social anxiety relief and inhibition reduction. These are framed as ALTERNATIVES — researchers select ONE acute option (Aniracetam, Phenibut, Pregabalin, or Propranolol) per event based on the symptom profile, with Memantine as an optional daily/preventative passive layer for chronic ruminative inhibition. The stack is positioned strictly as research-use-only (RUO) and Sean explicitly recommends Exposure Therapy and conventional therapy as first-line treatments before any pharmacological approach.
Key Benefits
Reduced social inhibition and 'awkwardness fear,' improved verbal fluidity and conversational flow, dampened physical symptoms of anxiety (tremors, shakiness, racing heart), reduced anticipatory anxiety and hypervigilance, lowered overexcitation tone, and — in the case of Memantine — passive reduction in self-monitoring rumination. Acute compounds work within 30-90 minutes; Memantine builds over weeks.
Mechanism of Action
Multi-pathway GABAergic, glutamatergic, and adrenergic modulation. Phenibut: GABA-B agonist + α2δ calcium-channel binding (gabapentinoid-like) producing anxiolysis and mild euphoria. Aniracetam: AMPA receptor positive allosteric modulator + cholinergic facilitation, with downstream anxiolytic and pro-social effects via dopamine/serotonin modulation. Pregabalin: α2δ subunit calcium-channel binding dampens neuronal excitability and glutamate release. Propranolol: non-selective β-adrenergic blockade reduces peripheral sympathetic symptoms (the 'physical' layer of anxiety) without direct CNS anxiolysis. Memantine: low-affinity uncompetitive NMDA antagonist that dampens excitatory glutamatergic tone while preserving normal signal transmission — passively reduces rumination and self-monitoring loops.
What to Expect
- Week 1Tolerability and dose-response.
- Week 2-4Early effect window.
- Week 4-8Peak benefit assessment.
- Week 8+Cycle decision point.
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.